Opioid benefits may not outweigh risks
After an extensive review, researchers said they were unsure whether the risks of prescription opioids outweighed the potential benefits for managing chronic pain.
After an extensive review, researchers said they were unsure whether the risks of prescription opioids outweighed the potential benefits for managing chronic pain.
“The efficacy of opioids and their suitability for the long-term management of chronic pain still remain very much in question….it stands in somewhat stark contrast to the clinical reality of chronic pain treatment, where rates of prescriptions have skyrocketed such that opioids are now among the most frequently prescribed medications,” wrote Kevin E. Vowles with the Department of Psychology at the University of New Mexico in Albuquerque, in the review published in the April, 2015, issue of Pain.
Vowles and his fellow researchers at the University of Washington in Seattle, Wash., and the UNM, found that the average rates of opioids misuse ranged between 21% and 29%. The rates of addiction averaged between 8% and 12%, while abuse was reported in only a single study.
Related: FDA: Final guidance on evaluation, labeling of abuse-deterrent opioids
After reviewing 38 published studies, most of which were conducted in the United States, the researchers discovered 2 primary implications. Misuse and addiction seem to be distinct patterns of problematic opioid use, and misuse seems more common than addiction. As a result, some misuses of prescription opioids may be addressed by “low-intensity intervention,” such as monthly counseling sessions, the researchers wrote.
Related: New HHS plan on opioids ups naloxone use
“If it is accurate that approximately one in four patients on opioids display patterns of opioid misuse, but not addiction, then perhaps more efficient targeting of treatment resources would be of benefit,” Vowles wrote. “Some forms of misuse, for example, may be readily addressed through relatively low-intensity methods such as education or frequent follow-up visits.”
One study in which monthly counseling sessions were provided showed that “there are alternatives available to providers who treat high-risk patients beyond simply not prescribing the medications at all,” Jowles wrote.
Read next: Babies exposed to narcotic pain relievers more likely to experience drug withdrawal syndrome
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
September 13th 2024Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There is no word yet on when Tecentriq Hybreza will be available or what the price will be.
Read More
FDA Warns of Liver Injury with Veozah for Hot Flashes
September 12th 2024The FDA has identified a probable case of serious drug induced liver injury that occurred in a woman in the United States who had received Veozah. The agency is requiring additional liver blood testing after starting therapy.
Read More
